Help and suppression in liver tolerance
肝脏耐受性的帮助和抑制
基本信息
- 批准号:9442460
- 负责人:
- 金额:$ 30.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-03-09 至 2019-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAllogenicAntigensAutoantigensBloodCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCellsChronicDataDependovirusEndothelial CellsFailureFeedbackFunctional disorderGenesHelper-Inducer T-LymphocyteHepatitisHepatitis BHepatocyteImmuneImmune ToleranceImmune systemImmunityImmunologicsImmunologyImmunosuppressionImmunosuppressive AgentsInfectionInterferon Type IIInterferon-alphaInterferonsInterleukin-10IntestinesIslets of LangerhansLinkLiteratureLiverMalignant NeoplasmsMediatingModelingNeoplasm MetastasisOrganPDCD1LG1 geneParasitesPlacentaPortal vein structurePropertyResearchResistanceRoleRouteSiteT-LymphocyteTNFSF6 geneTestingTissuesTransgenesTransgenic MiceTransplantationTransplanted tissueVirusbasebody systemcell typeexhaustionimmunogenicimmunopathologyinterestliver functionliver transplantationloss of functionmouse modelnovelunpublished works
项目摘要
Description: Liver tolerance was first identified in the 1960s in the context of experimental liver
transplantation. In many species, an allogeneic liver transplant will survive in an immune-competent
recipient, without immunosuppression. This reveals an underlying bias towards immune tolerance to
multiple liver antigens, including those encoded by transgenes (neo-self antigens), viruses and
parasites. Many mechanisms have been proposed to explain liver tolerance, but there is no satisfactory
model that unites them. The purpose of this project is to test two potential mechanisms and determine if
they are mechanistically linked.
Abundant evidence, including some generated by our lab, supports the concept that failure of CD8+ T
cell immunity in the liver is due to lack of CD4+ T cell help, resulting in CD8+ T cell loss of function
and clonal exhaustion. Other evidence, including Preliminary Data we present here, suggests that
immunosuppressive molecules are induced in liver cells, in particular Liver Sinusoidal Endothelial
Cells, by Interferon‐gamma. Our central novel idea is that these two mechanisms of tolerance are
linked, and the Preliminary Data strongly implicate Liver Sinusoidal Endothelial cells. In Specific Aim
1 we will test the hypothesis that Liver Sinusoidal Endothelial Cells are central in controlling CD4+ T
cell activation and thereby immunity versus tolerance, while in Specific Aim 2 we will test whether
Interferon‐gamma regulates the function of Liver Sinusoidal Endothelial Cells to induce tolerance. We
have optimized an AAV‐based model of liver tolerance to test these concepts, however the possibility
remains open that they are unique to the model. Therefore in Specific Aim 3 we test the same concepts
in a mouse model of Hepatitis B infection. If the concepts hold in both models, we argue that they
reveal a generally applicable mechanism of tolerance.
The relationship between IFN‐induced negative feedback, also known as Adaptive Tolerance, and
CD4+ T cell help may hold in other tissues. Therefore, clarification of this relationship will be of broad
immunological interest, and may have significance in models of infection, immunity and
immunopathology in many organ systems.
描述:肝耐受在20世纪60年代首次在实验性肝脏的背景下被发现。
移植。在许多物种中,同种异体肝移植将存活在具有免疫能力的
受体,无免疫抑制。这揭示了一种对免疫耐受的潜在偏见
多种肝脏抗原,包括由转基因(新自身抗原)、病毒和
寄生虫。已经提出了许多机制来解释肝脏耐受,但没有令人满意的机制。
将他们团结在一起的模型。该项目的目的是测试两种可能的机制,并确定
它们在机械上是相连的。
大量的证据,包括我们的实验室产生的一些故障,支持了导致CD8+CDT故障的新概念。
慢性肝病的细胞免疫功能障碍可能是由于缺乏CD8+T细胞的帮助,导致CD8+T细胞功能丧失。
和克隆人的精疲力竭。其他的证据,包括我们在这里展示的初步数据,都表明了这一点。
免疫抑制分子在肝细胞,尤其是肝窦内皮细胞中被诱导分化。
细胞,由干扰素-伽马研究。我们最新的中心想法是,这两种免疫耐受机制是相互作用的。
这些初步数据将有力地牵涉到肝窦内皮细胞。这是一个具体的目标。
1.我们将进一步检验这一假说,即肝脏和肝窦内皮细胞是控制CD4+T细胞的中枢。
细胞周期激活,从而提高免疫力,而不是耐受性,而在具体的免疫目标2中,我们将不会测试是否。
干扰素-γ可调节肝窦内皮细胞的免疫功能,从而诱导免疫耐受。
我们已经优化了一个基于AAV的肝脏耐受性测试模型,以进一步测试这些新概念,但考虑到了这种可能性。
他们仍然是开放的,因为他们是建立这种模式的独特工具。因此,在一个具体的目标中,我们将测试这些相同的概念。
在一个乙肝病毒感染的小鼠模型中,如果这两个概念在这两个模型中都成立,那么我们可以争辩说,它们是相同的。
揭示了一种普遍适用的容错机制。
--
这种关系是由干扰素诱导的负反馈,也被称为适应性免疫耐受性、耐受性和适应性。
CD_4~+T细胞可能在其他组织中起作用。因此,澄清这一关系将是非常广泛的。
免疫球蛋白、免疫球蛋白和免疫球蛋白在人类感染、免疫球蛋白和免疫球蛋白等动物模型中可能具有重要意义。
免疫病理学存在于许多重要的器官系统中。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ian NICHOLAS Crispe其他文献
Ian NICHOLAS Crispe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ian NICHOLAS Crispe', 18)}}的其他基金
NOVEL REVERSE ADJUVANT FOR VACCINE ENHANCEMENT
用于增强疫苗效果的新型反向佐剂
- 批准号:
7573075 - 财政年份:2009
- 资助金额:
$ 30.17万 - 项目类别:
NOVEL REVERSE ADJUVANT FOR VACCINE ENHANCEMENT
用于增强疫苗效果的新型反向佐剂
- 批准号:
7914396 - 财政年份:2009
- 资助金额:
$ 30.17万 - 项目类别:
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 30.17万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 30.17万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 30.17万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 30.17万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 30.17万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 30.17万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 30.17万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 30.17万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 30.17万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 30.17万 - 项目类别:
Grant-in-Aid for Scientific Research (B)














{{item.name}}会员




